Densys3D Announces US Dental Depot as Regional US Distributor
Densys3d has entered into a strategic agreement with US Dental Depot as a regional distributor for their intraoral scanner, MIA3D software, and speed scanner spray. This
Hadassah Hebrew U BioDesign Project, CardioVia, Raises NIS 3 Million & Was Accepted to the NGT3 VC Incubator
Following the June 2018 presentation of bio-med projects in the framework of the BioDesign, a joint program of Hadassah Medical Center and the Hebrew University
NovellusDx Inks Japan Distribution Deal for Cancer Treatment Response Assay
NovellusDx said today that it has signed a deal with Primetech to distribute its u Functional Annotation for Cancer Treatment (FACT) assay in Japan. NovellusDx brings
Sight Diagnostics Offers an AI-based Diagnostics Device for Faster Blood Tests
Sight Diagnostics, an Israeli medical devices startup in Jerusalem that’s using computer vision and machine learning technology to speed up blood testing, is launching a
Behavioral Health Care Management Startup Valera Health adds Eau Claire Group Health Cooperative to Customer Base
Valera Health, a behavioral healthcare management startup that developed an app to help clinicians remotely monitor patients with anxiety and depression, added Wisconsin health maintenance
NovaSight diagnoses and treats Lazy Eye and Concentration Problems by Monitoring Eye Movement
NovaSight system diagnoses eye problems in children and makes it possible to train the eyes in cases of amblyopia (lazy eye) and convergence insufficiency (CI). The
BrainsWay Receives First Ever FDA Clearance of a Non-Invasive Device for Treatment of Obsessive Compulsive Disorder
This clearance marks the second indication granted for BrainsWay Deep TMS. The first clearance was for treatment of Major Depressive Disorder in 2013 August 19,
US Patent Office Grants NOVELLUSDX Patent for Methods & Systems for identifying Patient-Specific Driver Mutations
NovellusDx, the leader in functional genomics, was granted from the US Patenet Office a new patent titled “METHODS AND SYSTEMS FOR IDENTIFYING PATIENT SPECIFIC DRIVER
BiondVax receives second €6M tranche disbursement from the European Investment Bank (EIB)
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, recently announced the receipt of a €6 million disbursement
